1-855-378-42281-855-378-4228
One of the outpatient rehab alternatives for individuals in Groton battling with opioid abuse and addiction is opioid maintenance therapy. Some facilities and doctors are certified to give certain medications to opioid addicted individuals, many that are opioids themselves and are addiction. In low enough amounts however, the individual doesn't feel high and also does not experience acute cravings and is not in opioid withdrawal. Methadone is the first drug used for this sole purpose, but there are alternative choices currently to choose from.
Methadone is an opioid and is meant to be taken at an outpatient medical center licensed to dispense the drug, which is taken on a daily basis in liquid or pill form. The cost of the drug is approximately one hundred and fifty dolloars a month. Buprenorphine is also an opioid based drug, and is a pill often taken one day on, one day off. But unlike Methadone that can only be administered in highly structured medical centers, Buprenorphine can be and is prescribed and administered in doctor's offices. The cost monthly of buprenorphine is approximately just under $300 /month for the generic of the medication. There is also a version of buprenorphine that contains the ingredient naloxone, which is a drug which reverses the effects of opioids. Someone consuming this version of the drug, AKA Suboxone, would find it harder to feel high from opioids if they relapsed while taking the drug. It too is taken on a daily basis, and is priced about $450 monthly. Naltrexone is another medication used in opioid maintenance therapy, but unlike the other drugs mentioned here it's an opiate blocker and isn't an opioid. There is an option to take this drug as a monthly shot, and that is called Vivitrol. As an opioid blocker, it prevents a person from experience being high from opioids, and in turn lowers the risk associated with relapse. This daily shot costs in the range of $1000 to $1200 a month.
For All Alcohol and Drug Treatment Facilities In Groton, Click Here.
